Drug delivery systems for differential release in combination therapy

Expert Opinion on Drug Delivery

Volumn 8, Issue 2, 2011, Pages 171-190

  Zhang, Hongbin ^a   Wang, Guojie ^a   Yang, Huai ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY BEIJING   (China)

Author keywords

combination therapy; delivery system; differential release; drug carrier; therapeutic agent

Indexed keywords

COMBRETASTATIN A4; CYTARABINE; DAUNORUBICIN; DENDRIMER; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; IRINOTECAN; ISONIAZID; LIPOSOME; MYCOPHENOLIC ACID; N (2 HYDROXYPROPYL)METHACRYLAMIDE; NANOCARRIER; NANOFIBROUS MAT; NANOPARTICLE; NANOSPHERE; PACLITAXEL; POLYMER; POLYMERSOME; PYRAZINAMIDE; RAPAMYCIN; RETASPIMYCIN; RIFAMPICIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; BIOASSAY; CARDIOTOXICITY; COMPOSITE MATERIAL; CRITICAL MICELLE CONCENTRATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; HUMAN; HYDROGEL; LIPID BILAYER; MICELLE; MICROPARTICLE ENZYME IMMUNOASSAY; NANOENCAPSULATION; NONHUMAN; REVIEW;

DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; NANOTECHNOLOGY;

EID: 79251529926     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2011.547470     Document Type: Review

References (100)

1. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145-60
2. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7:771-82
3. Agnihotri S, Mallikarjuna N, Aminabhavi T. Recent advances on chitosan-based micro-and nanoparticles in drug delivery. J Control Release 2004;100:5-28
4. Kakizawa Y, Kataoka K. Block copolymer micelles for delivery of gene and related compounds. Adv Drug Deliv Rev 2002;54:203-22
5. Hoare TR, Kohane DS. Hydrogels in drug delivery: progress and challenges. Polymer 2008;49:1993-2007
6. Allen TM, Cullis PR Drug delivery systems: entering the mainstream. Science 2004;303:1818-22
7. Makin G, Dive C. Apoptosis and cancer chemotherapy. Trends Cell Biol 2001;11:S22-6
8. Markman M. Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary. Expert Opin Pharmacother 2006;7:1469-74
9. Rosenthal E, Poizot-Martin I, Saint-Marc T, et al. Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma. Am J Clin Oncol Canc 2002;25:57-9
10. Wang JC, Goh BC, Lu WL, et al. In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol Pharm Bull 2005;28:822-8
11. Wu J, Lu YH, Lee A, et al. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci 2007;10:350-7
12. Saxon DN, Mayer LD, Bally MB. Liposomal anticancer drugs as agents to be used in combination with other anticancer agents: studies on a liposomal formulation with two encapsulated drugs. J Liposome Res 1999;9:507-22
13. Abraham SA, McKenzie C, Masin D, et al. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin Cancer Res 2004;10:728-38
14. Tardi PG, Gallagher RC, Johnstone S, et al. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Bba-Biomembranes 2007;1768:678-87
15. GursoyA, Kut E, Ozkirimli S. Co-encapsulation of isoniazid and rifampicin in liposomes and characterization of liposomes by derivative spectroscopy. Int J Pharm 2004;271:115-23
16. Zhang Y-F, Wang J-C, Bian D-Y, et al. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Eur J Pharm Biopharm 2010;74:467-73
17. Xiao W, Chen X, Yang L, et al. Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome. Int J Pharm 2010;393:120-7
18. Pakunlu R, Wang Y, Saad M, et al. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J Control Release 2006;114:153-62
19. Provoda CJ, Stier EM, Lee KD. Tumor cell killing enabled by listeriolysin O-liposome-mediated delivery of the protein toxin gelonin. J Biol Chem 2003;278:35102-8
20. Shin H-C, Alani AWG, Rao DA, et al. Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs. J Control Release 2009;140:294-300
21. Wang Y, Gao S, Ye W-H, et al. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater 2006;5:791-6
22. Zhu C, Jung S, Luo S, et al. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. Biomaterials 2010;31:2408-16
23. Zhu J-L, Cheng H, Jin Y, et al. Novel polycationic micelles for drug delivery and gene transfer. J Mater Chem 2008;18:4433
24. Wiradharma N, Tong YW, Yang Y-Y. Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect. Biomaterials 2009;30:3100-9
25. Qiu LY, Bae YH. Self-assembled polyethylenimine-graft-poly (epsi-caprolactone) micelles as potential dual carriers of genes and anticancer drugs. Biomaterials 2007;28:4132-42
26. Lee A, Wang Y, Cheng H, et al. The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. Biomaterials 2009;30:919-27
27. Lee JS, Bae JW, Joung YK, et al. Controlled dual release of basic fibroblast growth factor and indomethacin from heparin-conjugated polymeric micelle. Int J Pharm 2008;346:57-63
28. Bae Y, Diezi T, Zhao A, et al. Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents. J Control Release 2007;122:324-30
29. Wang Z, Ho PC A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities. Biomaterials 2010;31:7115-23
30. Yin C, Li X, Wu Q, et al. Multidrug nanoparticles based on novel random copolymer containing cytarabine and fluorodeoxyuridine. J Colloid Interface Sci 2010;349:153-8
31. Greco F, Vicent MJ. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev 2009;61:1203-13
32. Duncan R, Kopeckovarejmanova P, Strohalm J, et al. Anticancer agents coupled to N-(2-hydroxypropyl) methacrylamide copolymers. 1. Evaluation of daunomycin and puromycin conjugates in vitro. Brit J Cancer 1987;55:165-74
33. Terwogt JMM, Huinink WWT, Schellens JHM, et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anti-Cancer Drug 2001;12:315-23
34. Vicent MJ, Greco F, Nicholson RI, et al. Polymer therapeutics designed for a combination therapy of hormone-dependent cancer. Angew Chem Int Ed 2005;44:4061-6
35. Greco F, Vicent MJ, Penning NA, et al. HPMA copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines. J Drug Target 2005;13:459-70
36. Greco F, Vicent M, Gee S, et al. Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells. J Control Release 2007;117:28-39
37. Miller K, Erez R, Segal E, et al. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew Chem Int Ed 2009;48:2949-54
38. Lammers T, Subr V, Ulbrich K, et al. Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials 2009;30:3466-75
39. Segal E, Pan H, Ofek P, et al. Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS ONE 2009;4:e5233
40. Krakovicova H, Etrych T, Ulbrich K. HPMA-based polymer conjugates with drug combination. Eur J Pharm Sci 2009;37:405-12
41. Nicoletti S, Seifert K, Gilbert IH. Water-soluble polymer-drug conjugates for combination chemotherapy against visceral leishmaniasis. Bioorgan Med Chem 2010;18:2559-65
42. Rihova B, Etrych T, Sirova M, et al. Synergistic action of doxorubicin bound to the polymeric carrier based on N-(2-hydroxypropyl)methacrylamide copolymers through amide or hydrazone bond. Mol Pharmaceut 2010;7:1027-40
43. Satchi-Fainaro R, Puder M, Davies JW, et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 2004;10:255-61
44. Santucci L, Mencarelli A, Renga B, et al. Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO-pegylated epirubicin. FASEB J 2006;20:765-73
45. Khandare JJ, Chandna P, Wang Y, et al. Novel polymeric prodrug with multivalent components for cancer therapy. J Pharmacol Exp Ther 2006;317:929-37
46. Pasut G, Scaramuzza S, Schiavon O, et al. PEG-epirubicin conjugates with high drug loading. J Bioact Compat Pol 2005;20:213-30
47. Khandare J, Minko T. Polymer-drug conjugates: progress in polymeric prodrugs. Prog Polym Sci 2006;31:359-97
48. Pasut G, Greco F, Mero A, et al. Polymer-drug conjugates for combination anticancer therapy: investigating the mechanism of action. J Med Chem 2009;52:6499-502
49. Santucci L, Mencarelli A, Renga B, et al. Cardiac safety and antiturnoral activity of a new nitric oxide derivative of pegylated epirubicin in mice. Anti-Cancer Drug 2007;18:1081-91
50. Kim E, Jung Y, Choi H, et al. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials 2010;31:4592-9
51. Chandna P, Saad M, Wang Y, et al. Targeted proapoptotic anticancer drug delivery system. Mol Pharmaceut 2007;4:668-78
52. Bagalkot V, Lee I-H, Yu MK, et al. A combined chemoimmunotherapy approach using a plasmid-doxorubicin complex. Mol Pharmaceut 2009;6:1019-28
53. Song XR, Zhao Y, Wu WB, et al. PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment efficiency. Int J Pharm 2008;350:320-9
54. Song XR, Cai Z, Zheng Y, et al. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur J Pharm Sci 2009;37:300-5
55. Song X, Zhao Y, Hou S, et al. Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm 2008;69:445-53
56. Aryal S, Hu C-MJ, Zhang L. Combinatorial drug conjugation enables nanoparticle dual-drug delivery. Small 2010;6:1442-8
57. Zhang L, Radovic-Moreno AF, Alexis F, et al. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem 2007;2:1268-71
58. Patil Y, Sadhukha T, Ma L, et al. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release 2009;136:21-9
59. Destache CJ, Belgum T, Christensen K, et al. Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC Infect Dis 2009;9:198. doi:10.1186/1471-2334-9-198
60. Soma CE, Dubernet C, Bentolila D, et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 2000;21:1-7
61. Wan A, Sun Y, Gao L, et al. Preparation of aspirin and probucol in combination loaded chitosan nanoparticles and in vitro release study. Carbohydr Polym 2009;75:566-74
62. Hammady T, Rabanel JM, Dhanikula RS, et al. Functionalized nanospheres loaded with anti-angiogenic drugs: cellular uptake and angiosuppressive efficacy. Eur J Pharm Biopharm 2009;72:418-27
63. Hammady T, El-Gindy A, Lejmi E, et al. Characteristics and properties of nanospheres co-loaded with lipophilic and hydrophilic drug models. Int J Pharm 2009;369:185-95
64. Diwan M, Tafaghodi M, Samuel J. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J Control Release 2002;85:247-62
65. Wong HL, Bendayan R, Rauth AM, et al. Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J Pharm Sci 2004;93:1993-2008
66. Shuhendler AJ, Cheung RY, Manias J, et al. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res Treat 2009;119:255-69
67. Wong H, Bendayan R, Rauth A, et al. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Release 2006;116:275-84
68. Xu Z, Zhang Z, Chen Y, et al. The characteristics and performance of a multifunctional nanoassembly system for the co-delivery of docetaxel and iSur-pDNA in a mouse hepatocellular carcinoma model. Biomaterials 2010;31:916-22
69. Yang J, Lee C-H, Ko H-J, et al. Multifunctional magneto-polymeric nanohybrids for targeted detection and synergistic therapeutic effects on breast cancer. Angew Chem Int Ed 2007;46:8836-9
70. Dilnawaz F, Singh A, Mohanty C, et al. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 2010;31:3694-706
71. Zhao LB, Cheng YY, Hu JJ, et al. Host-guest chemistry of dendrimer-drug complexes. 3. Competitive binding of multiple drugs by a single dendrimer for combination therapy. J Phys Chem B 2009;113:14172-9
72. Ren Y, Kang CS, Yuan XB, et al. Co-delivery ofas-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro. J Biomat Sci Polym E 2010;21:303-14
73. Ahmed F, Pakunlu R, Brannan A, et al. Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug. J Control Release 2006;116:150-8
74. Chen AM, Zhang M, Wei D, et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 2009;5:2673-7
75. Sengupta S, Eavarone D, Capila I, et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005;436:568-72
76. Hussain M, Beale G, Hughes M, et al. Co-delivery of an antisense oligonucleotide and 5-fluorouracil using sustained release poly (lactide-co-glycolide) microsphere formulations for potential combination therapy in cancer. Int J Pharm 2002;234:129-38
77. UL-Ain Q, Sharma S, Khuller GK. Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis. Antimicrob Agents Ch 2003;47:3005-7
78. Dutt M, Khuller GK. Chemotherapy of mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in poly (DL-lactide-co-glycolide) microparticles. J Antimicrob Chemother 2001;47:829-35
79. Roman BS, Irache JM, Gomez S, et al. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology. Eur J Pharm Biopharm 2008;70:98-108
80. Lamprecht A, Torres HR, Schafer U, et al. Biodegradable microparticles as a two-drug controlled release formulation: a potential treatment of inflammatory bowel disease. J Control Release 2000;69:445-54
81. Perez MH, Zinutti C, Lamprecht A, et al. The preparation and evaluation of poly(epsilon-caprolactone) microparticles containing both a lipophilic and a hydrophilic drug. J Control Release 2000;65:429-38
82. Krishnamachari Y, Salem AK. Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv Drug Deliv Rev 2009;61:205-17
83. Beaudette TT, Bachelder EM, Cohen JA, et al. In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines. Mol Pharmaceut 2009;6:1160-9
84. Tafaghodi M, Tabassi SAS, Jaafari MR. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN. Int J Pharm 2006;319:37-43
85. Zhang XQ, Dahle CE, Baman NK, et al. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles. J Immunother 2007;30:469-78
86. Liu Z, Wu XY, Bendayan R. In vitro investigation of ionic polysaccharide microspheres for simultaneous delivery of chemosensitizer and antineoplastic agent to multidrug-resistant cells. J Pharm Sci 1999;88:412-18
87. Manna U, Patil S. Dual drug delivery microcapsules via layer-by-layer self-assembly. Langmuir 2009;25:10515-22
88. Peppas NA, Hilt JZ, Khademhosseini A, et al. Hydrogels in biology and medicine: from molecular principles to bionanotechnology. Adv Mater 2006;18:1345-60
89. Bouhadir KH, Alsberg E, Mooney DJ. Hydrogels for combination delivery of antineoplastic agents. Biomaterials 2001;22:2625-33
90. Zhang H, Zhao C, Cao H, et al. Hyperbranched poly(amine-ester) based hydrogels for controlled multi-drug release in combination chemotherapy. Biomaterials 2010;31:5445-54
91. Konishi M, Tabata Y, Kariya M, et al. In vivo anti-tumor effect of dual release of cisplatin and adriamycin from biodegradable gelatin hydrogel. J Control Release 2005;103:7-19
92. Baumann MD, Kang CE, Stanwick JC, et al. An injectable drug delivery platform for sustained combination therapy. J Control Release 2009;138:205-13
93. Xu X, Chen X, Wang Z, et al. Ultrafine PEG-PLA fibers loaded with both paclitaxel and doxorubicin hydrochloride and their in vitro cytotoxicity. Eur J Pharm Biopharm 2009;72:18-25
94. Yan S, Xiaoqiang L, Shuiping L, et al. Controlled release of dual drugs from emulsion electrospun nanofibrous mats. Colloids Surf B 2009;73:376-81
95. Okuda T, Tominaga K, Kidoaki S. Time-programmed dual release formulation by multilayered drug-loaded nanofiber meshes. J Control Release 2010;143:258-64
96. Wei L, Cai C, Lin J, et al. Dual-drug delivery system based on hydrogel/micelle composites. Biomaterials 2009;30:2606-13
97. Kim BS, Smith RC, Poon Z, et al. MAD (multiagent delivery) nanolayer: delivering multiple therapeutics from hierarchically assembled surface coatings. Langmuir 2009;25:14086-92
98. Xia W, Chang J, Lin J, et al. The pH-controlled dual-drug release from mesoporous bioactive glass/polypeptide graft copolymer nanomicelle composites. Eur J Pharm Biopharm 2008;69:546-52
99. Singh A, Suri S, Roy K. In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA-DNA carrying microparticles to dendritic cells. Biomaterials 2009;30:5187-200
100. Mandal BB, Kundu SC Calcium alginate beads embedded in silk fibroin as 3D dual drug releasing scaffolds. Biomaterials 2009;30:5170-7